Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-Current Deffered Revenue (2016 - 2019)

Historic Non-Current Deffered Revenue for Outlook Therapeutics (OTLK) over the last 5 years, with Q2 2019 value amounting to $3.5 million.

  • Outlook Therapeutics' Non-Current Deffered Revenue rose 1540.94% to $3.5 million in Q2 2019 from the same period last year, while for Jun 2019 it was $3.5 million, marking a year-over-year increase of 1540.94%. This contributed to the annual value of $2.8 million for FY2018, which is 3825.06% down from last year.
  • Outlook Therapeutics' Non-Current Deffered Revenue amounted to $3.5 million in Q2 2019, which was up 1540.94% from $4.1 million recorded in Q1 2019.
  • In the past 5 years, Outlook Therapeutics' Non-Current Deffered Revenue ranged from a high of $12.7 million in Q3 2015 and a low of $2.8 million during Q3 2018
  • Its 5-year average for Non-Current Deffered Revenue is $4.8 million, with a median of $4.5 million in 2017.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first tumbled by 5950.74% in 2016, then skyrocketed by 2346.5% in 2019.
  • Outlook Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $12.7 million in 2015, then tumbled by 61.89% to $4.9 million in 2016, then dropped by 16.87% to $4.0 million in 2017, then rose by 16.58% to $4.7 million in 2018, then decreased by 24.84% to $3.5 million in 2019.
  • Its Non-Current Deffered Revenue was $3.5 million in Q2 2019, compared to $4.1 million in Q1 2019 and $4.7 million in Q4 2018.